Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperemia Clear all
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

NCT06735599
View directory record Official record
Conditions
Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure, Male, Female, Adult, Cognition, Endothelial Function (Reactive Hyperemia), Oxidative Stress, Diet, Overweight, Body Composition Measurement, Gut Microbiome, Arterial Stiffness, Caucasian Whites, Inflammation, Microvascular Function
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Phase 3 Interventional

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

NCT06945315
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
RALP (Robotic-assisted radical prostatectomy), SAFE (Saline assisted fascial engorgement)
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Heat Therapy, Functional Capacity, and Vascular Health in Older Adults

NCT05706181
View directory record Official record
Conditions
Aging Well, Walking, Difficulty, Hyperemia
Interventions
Home-based leg heat therapy, Home-based sham therapy
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
55 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate Supplementation and Muscle Blood Flow

NCT03459027
View directory record Official record
Conditions
Vasodilation, Blood Pressure, Active Hyperemia, Aging
Interventions
Super Beets, Beetroot powder
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
60 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

Diastolic Hyperemia Free Index for Assessment of Moderate Coronary Stenoses

NCT04019535
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
physiological assessment with Volcano Verrata pressure wire (iFR)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Results available

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

NCT01161121
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
adenosine, regadenoson
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Jacksonville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02188160
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121, Placebo
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Engorgement Study With a Double Electric Breast Pump

NCT01619371
View directory record Official record
Conditions
Engorgement
Interventions
Simplisse Double Electric Breast Pump
Device
Lead sponsor
Foundation for Maternal Infant and Lactation Knowledge
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

NCT06735651
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Repletion in Coronary Artery Disease

NCT01570309
View directory record Official record
Conditions
Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
Interventions
Ergocalciferol, Sugar pill
Drug · Other
Lead sponsor
Seth I. Sokol, M.D.
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

NCT01959243
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

NCT06029673
View directory record Official record
Conditions
Lactation Suppressed
Interventions
Cabergoline 1 MG, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

NCT00539526
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 5, 2026, 9:15 AM EDT
Not listed No phase listed Observational

Renal Autotransplantation; Case Series

NCT05115812
View directory record Official record
Conditions
Renal Vascular Disease, Nutcracker Syndrome, Renal, Pelvic Trauma, Loin Pain-Hematuria Syndrome, Renal Tumor, Congestion, Venous
Interventions
Pre-Operative Information, Intra-Operative Data, Post-Operative Data (up to discharge), Short-Term Follow-Up Data
Procedure · Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 5, 2026, 9:15 AM EDT
Not yet recruiting Phase 3 Interventional

An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults

NCT07578363
View directory record Official record
Conditions
Ocular Hyperemia
Interventions
Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes Autonomic and Vascular Function

NCT06786546
View directory record Official record
Conditions
Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Diabetes, Autoimmune
Interventions
Not listed
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

NCT02039765
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine tartrate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

NCT00640458
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Sildenafil 100 mg, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Peanuts for Cardiometabolic, Brain, and Intestinal Health

NCT06867198
View directory record Official record
Conditions
Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Cognition, Microvascular Function, Gut Microbiota, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Blood Pressure, Adult
Interventions
Peanuts
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 59 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 9:15 AM EDT